Morphosys pays $20M for Emergent's bispecific MAb outside N. America
DUBLIN – Morphosys AG is taking a first step into bispecific antibody development by licensing ex-North American rights to Emergent Biosolutions Inc.'s cancer immunotherapeutic ES414, in return for $20 million up front and milestones totaling $163 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST